traveling with tirzepatide Zepbound: TSA Rules, Storage & Cooling Tips How To Keep Tirzepatide Cold

The data of 4,887 participants treated with tirzepatide and those of the 2,328 control participants were analysed

Schedule a nutrition-focused check-in at the 6-week and 12-week marks of treatment to reassess how you're tolerating the medication and whether your supplement plan is working

Dulaglutide as add-on therapy to Sglt2 inhibitors in patients with inadequately controlled type 2 diabetes (Award-10): a 24-week, randomised, double-blind, placebo-controlled trial

Novo Nordisks #Semaglutide #Fails in #Alzheimers #EVOKE #Trials Show #No #Cognitive #Benefit Despite Biomarker Signals A highly anticipated moment at #ADPD2026 delivered a sobering outcome: Oral semaglutide failed to improve cognition or function in early Alzheimers EVOKE & EVOKE+ trials showed no difference vs placebo at 104 weeks Yet biomarker changes (#pTau181 ~10%) were observed Key findings from EVOKE / EVOKE+ 1 No clinical efficacy Primary endpoint (CDR-SB): no improvement Secondary endpoints (ADCS-ADL, MMSE, ADAS-Cog): no signal No delay in MCI Alzheimers progression 2 Biomarker disconnect CSF p-tau181 reduced (~10%) But no translation into clinical benefit 3 No responder subgroup No efficacy signal across age, BMI, T2D, sex, or race Why this matters 1 GLP-1 hype meets neurological reality Metabolic success neurodegenerative success Mechanisms dont simply transfer across disease domains 2 Biomarkers outcomes Even statistically significant changes May still be clinically meaningless 3 Rethinking Alzheimers biology Amyloid/tau biomarkers may not capture full disease complexity Especially for non-amyloid mechanisms 4 Strategic implications Expanding GLP-1 into CNS now looks riskier Pipeline prioritization will shift toward target-specific neurobiology My takeaway 1 The Alzheimers field still lacks validated translational endpoints 2 Biomarker-driven optimism must be matched with clinical reality 3 Cross-indication drug expansion requires mechanistic precisionnot trend following Bottom line: Novo Nordisks setback highlights a critical truth In Alzheimers, biology is still king and shortcuts dont work #Alzheimers #ADPD2026 #DrugDevelopment #Biotech #Neuroscience #GLP1 #ClinicalTrials A meaningful reality check for the field

FOXA1 overexpression suppresses interferon signaling and immune response in cancer

Key takeaways The price you pay for Ozempic (semaglutide) may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use